[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-1-en-105":3,"doc-seo-240329-105":53,"doc-detail-240329-en":127},{"code":4,"msg":5,"data":6},0,"success",[7,14,19,24,29,34,39,44,49],{"id":8,"doc_module":9,"doc_module_name":10,"category_name":11,"show_sort_weight":12,"slug":13},11,1,"Template","Presentations",90,"presentations",{"id":15,"doc_module":9,"doc_module_name":10,"category_name":16,"show_sort_weight":17,"slug":18},12,"Resumes",80,"resumes",{"id":20,"doc_module":9,"doc_module_name":10,"category_name":21,"show_sort_weight":22,"slug":23},14,"Invoices",70,"invoices",{"id":25,"doc_module":9,"doc_module_name":10,"category_name":26,"show_sort_weight":27,"slug":28},15,"Posters",60,"posters",{"id":30,"doc_module":9,"doc_module_name":10,"category_name":31,"show_sort_weight":32,"slug":33},16,"Social Media",50,"social-media",{"id":35,"doc_module":9,"doc_module_name":10,"category_name":36,"show_sort_weight":37,"slug":38},17,"Forms",40,"forms",{"id":40,"doc_module":9,"doc_module_name":10,"category_name":41,"show_sort_weight":42,"slug":43},18,"Letters",30,"letters",{"id":45,"doc_module":9,"doc_module_name":10,"category_name":46,"show_sort_weight":47,"slug":48},21,"Paper Templates",5,"papers-templates",{"id":50,"doc_module":9,"doc_module_name":10,"category_name":51,"show_sort_weight":4,"slug":52},158,"General","general-158",{"code":4,"msg":54,"data":55},"ok",{"site_id":56,"language":57,"slug":58,"title":59,"keywords":60,"description":61,"schema_data":62,"social_meta":120,"head_meta":122,"extra_data":124,"updated_unix":126},105,"en","counteract-milestone-template-examples","CounterACT MILESTONE TEMPLATE EXAMPLES","","This document provides examples of milestone templates for the CounterACT program, outlining success criteria for biological activity in various applications. Milestone #1, occurring in Year 01, focuses on achieving requisite biological activity for both hit/lead optimization and target identification/validation. For hit/lead work, success criteria are defined for different tissues (Eye, Lung, Skin), emphasizing percentage reduction in outcome measures and minimal cytotoxicity. For target identification/validation, criteria include a specific percentage increase/decrease in target activity and selectivity measures. The document stresses that 'X' represents a justifiable number for biological and clinical relevance, and criteria can be tailored per compound or made generic. It also highlights that the stringency of these thresholds should increase annually to serve as decision points for continued work and to align with overall project goals for subsequent years.",{"@graph":63,"@context":119},[64,80,102],{"@type":65,"itemListElement":66},"BreadcrumbList",[67,71,74,77],{"item":68,"name":69,"@type":70,"position":9},"https://docshare.wps.com","Home","ListItem",{"item":72,"name":10,"@type":70,"position":73},"https://docshare.wps.com/template/",2,{"item":75,"name":36,"@type":70,"position":76},"https://docshare.wps.com/template/forms/",3,{"item":78,"name":59,"@type":70,"position":79},"https://docshare.wps.com/template/counteract-milestone-template-examples/240329/",4,{"url":78,"name":59,"@type":81,"image":82,"author":87,"headline":59,"publisher":90,"fileFormat":93,"inLanguage":57,"description":61,"dateModified":94,"datePublished":95,"encodingFormat":93,"isAccessibleForFree":96,"interactionStatistic":97},"DigitalDocument",{"url":83,"@type":84,"width":85,"height":86},"https://docshare.wps.com/thumbnails/counteract-milestone-template-examples/240329.png","ImageObject",442,249,{"name":88,"@type":89},"Theodore","Person",{"url":68,"name":91,"@type":92},"DocShare","Organization","application/pdf","2026-10-30","2026-09-11",true,{"@type":98,"interactionType":99,"userInteractionCount":101},"InteractionCounter",{"@type":100},"ViewAction",6,{"@type":103,"mainEntity":104},"FAQPage",[105,111,115],{"name":106,"@type":107,"acceptedAnswer":108},"What is the purpose of the CounterACT Milestone Template Examples?","Question",{"text":109,"@type":110},"The document provides examples of milestone templates for the CounterACT program, outlining success criteria for biological activity essential for hitting and lead optimization, as well as target identification and validation work.","Answer",{"name":112,"@type":107,"acceptedAnswer":113},"What are the key success criteria for Milestone #1 in Year 01 for hit/lead work?",{"text":114,"@type":110},"For hit/lead work, success criteria include achieving a specific percentage reduction in outcome measures (e.g., for Eye, Lung, Skin applications) and maintaining minimal cytotoxicity (less than X% in tests).",{"name":116,"@type":107,"acceptedAnswer":117},"How are success criteria defined for target identification/validation in Milestone #1?",{"text":118,"@type":110},"For target identification/validation, Milestone #1 requires a chemical agent to cause a 50% increase or decrease in target activity and to demonstrate selectivity measures against other targets.","https://schema.org",{"og:url":78,"og:type":121,"og:title":59,"og:site_name":91,"og:description":61},"article",{"robots":123,"canonical":78},"index,follow",{"doc_id":125,"site_id":56},240329,1790486759,{"code":4,"msg":5,"data":128},{"doc_id":125,"user_id":129,"nickname":88,"user_avatar":130,"doc_module":9,"category_id":35,"category_name":36,"doc_title":59,"doc_description":61,"doc_content":131,"file_id":132,"file_url":133,"file_type":134,"file_size":135,"view_count":101,"is_deleted":4,"is_public":9,"is_downloadable":9,"audit_status":9,"page_count":9,"language":136,"language_code":57,"site_id":56,"html_lang":57,"table_of_contents":137,"faqs":138,"seo_title":139,"seo_description":61,"update_tm":140,"read_time":4},7971461740886,"https://ap-avatar.wpscdn.com/davatar_3d24733baf745e90a7e4bdd5f77d97b2","CounterACT MILESTONE TEMPLATE EXAMPLES  \n…for hits or leads you are working with, e.g. in different tissues Milestone \\#1 . Year 01 Requisite Biological Activity for hits/leads:  \na) Eye: Success Criteria:  \na. X% reduction in your outcome measure  \nb. X% reduction in another outcome measure (if applicable; you can use 1, 2 or any number of outcome measures)  \nc. Less than X% cytotoxicity in culture or in vivo tests  \nb) Lung: Success Criteria  \na.    \nb.    \nc.    \nc) Skin: Success Criteria  \na.    \nb.    \nc.    \n- X represents some number that you can justify as biologically and clinically relevant.  \n-  These criteria can apply to only one compound your studying and you can present a separate set of criteria for another compound. Or you can make them generic such that ANY compound that you’re studying must meet these criteria.  \n…for model development and target identification/validation work  \nMilestone \\#1 . Year 01 Requisite Biological Activity for Target Identification/Validation:  \na) Chemical agent causes 50% increase/decrease in target activity  \na. Selectivity measures (against other targets)  \nNote: the above examples should be used to put in place some sort of threshold of scientific accomplishment that serves as a decision point to “go” or “no go”for that aspect of your study, as you plan for Year 02. If you continue working with a particular compound or target, the stringency for threshold accomplishment should increase with each successive year until you have met your overall goal.","cbCaibTRPT756LyV","https://ap.wps.com/l/cbCaibTRPT756LyV","pdf",15931,"English","# CounterACT MILESTONE TEMPLATE EXAMPLES\n## Milestone #1 . Year 01 Requisite Biological Activity for hits/leads:\n### a) Eye: Success Criteria:\n### b) Lung: Success Criteria\n### c) Skin: Success Criteria\n## Milestone #1 . Year 01 Requisite Biological Activity for Target Identification/Validation:","[{\"question\":\"What is the purpose of the CounterACT Milestone Template Examples?\",\"answer\":\"The document provides examples of milestone templates for the CounterACT program, outlining success criteria for biological activity essential for hitting and lead optimization, as well as target identification and validation work.\"},{\"question\":\"What are the key success criteria for Milestone #1 in Year 01 for hit/lead work?\",\"answer\":\"For hit/lead work, success criteria include achieving a specific percentage reduction in outcome measures (e.g., for Eye, Lung, Skin applications) and maintaining minimal cytotoxicity (less than X% in tests).\"},{\"question\":\"How are success criteria defined for target identification/validation in Milestone #1?\",\"answer\":\"For target identification/validation, Milestone #1 requires a chemical agent to cause a 50% increase or decrease in target activity and to demonstrate selectivity measures against other targets.\"}]","CounterACT MILESTONE TEMPLATE EXAMPLES | PDF",1789160045]